Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia
This Research Article, published in Future Oncology, provides a detailed comparison of zanubrutinib and acalabrutinib for relapsed/refractory chronic lymphocytic leukemia patients. View the full article Abstract Aims: In the absence of head-to-head comparative trials, this study aimed to compare zanubrutinib versus acalabrutinib in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) by calculating number needed to treat … Read more